Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. - Wikidata - wikimedia - TriplyDB

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

http://www.wikidata.org/entity/Q39640585

about

Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.Emerging monoclonal antibodies against Clostridium difficile infection.Bezlotoxumab for the prevention of Clostridium difficile recurrence.Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.Collateral damage during antibiotic treatment of C. difficile infection in the aged host: Insights into why recurrent disease happens.Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection.Editorial Commentary: Where to Place the New Treatments for Clostridium difficile Infection?A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection.Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

P2860

Q38686710-38428B1F-0B72-421F-A24F-CD1FD8B43564 Q38755888-999A4266-656B-4D12-974B-5BFFF5AE2D37 Q39145792-1AEB4AE2-E766-4412-A4CC-9791BFC41535 Q39168914-42A7F9AF-D2EB-4636-B409-43CE79FFFC97 Q40095035-CA7EDC40-A219-49BC-AADD-B73C82F32995 Q40125340-03C3D600-62E4-4E9F-A0FA-960D1AFCEF0B Q40233875-9DFC24F8-CEDB-4D60-B20D-7EC9FAA0834A Q41996759-E45F5BD7-28A1-4B3D-AB3A-3D55E5E06371 Q42336377-F6069F8C-F07F-4D92-A80C-58DA175F65BB Q48174220-D34DC7E3-962A-4800-83DE-A4CC4E8F2834 Q49201152-318CADC4-11E1-4B69-BA90-F3A0113365C9 Q55103812-CFA88B45-CB13-497C-BB13-3191BF15644E Q55220241-3E3F83EA-7C87-4A4C-8028-FF051A516197 Q57455315-1933316D-D741-4643-8D31-F97E9E44E7EC

P2860

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

http://www.wikidata.org/entity/Q39640585

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

@en

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

@nl

type

label

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

@en

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

@nl

prefLabel

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

@en

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

@nl

P1433

Q39640585-2D6C1A0D-6392-4E23-9A99-6B1A611B5D2F

P1476

Q39640585-14F082FD-00E9-4C83-9DEF-360D70F90D0B

P2093

Q39640585-0FBFF560-5365-4AD3-8C50-D8D1EF88CD3D

Q39640585-400D164A-DE8A-47A9-B0AB-45C0B7BAF7BA

Q39640585-4252589B-B832-4E9D-AF4A-9D74C9C04455

Q39640585-4A6AC632-701F-475E-A10E-900F5389BF97

Q39640585-4C1D4108-A9F4-4E04-B9DF-3A0D39CCE853

Q39640585-6B9E85DA-871F-4071-A37F-D7A414BE4864

Q39640585-759FAAF6-FC61-476C-A6E6-504AD4159FBF

Q39640585-89E8DDA8-D282-46F5-9EA7-D5468E509E4B

Q39640585-AE4B2A9E-CBA3-4A1E-AFB3-2F4FF482E77F

Q39640585-D5E44C0E-FCB9-4FF3-B327-9B4E3756B293

P2860

Q39640585-0E3596EF-BB5D-4BC1-AA4C-6BE694D08F73

Q39640585-1079BF7E-B34F-499F-AFFC-70B9708D4B30

Q39640585-28B42653-AD47-4661-81E4-CE03EB9BC7A2

Q39640585-40AFDB80-9CD3-4083-BCC1-625057F0A2CF

Q39640585-4130C602-AC98-468C-A157-04EDB562A56F

Q39640585-48D26701-8517-4BA8-9977-6E7FE0192EA6

Q39640585-523D5765-0B73-4A9A-81F7-6F5741092B09

Q39640585-5A713336-FD7F-4AE7-ACEB-17DADA928F39

Q39640585-5D0AD18A-BD2B-4112-ABEB-586206BD401F

Q39640585-5DCC33C7-BA3D-4EEB-9661-B823A3FCBFD0

P304

Q39640585-19E9447C-24C4-4A15-9ABA-E4261DD2A42D

P31

Q39640585-ED9E515E-D19E-4B62-B917-0D8CAB3FD55C

P356

Q39640585-0623BD08-97A2-441D-9323-467B67D6F6EE

P407

Q39640585-BA577C89-9DC3-41D8-8836-B43B0A86F9FF

P433

Q39640585-7182B7BF-17B4-4600-8305-D536A5AB72F4

P478

Q39640585-94161D86-BC1C-41F5-BB87-F8B65BB34529

P50

Q39640585-E7BC12FF-7587-4DD0-B94C-B12D376267CD

P577

Q39640585-C608D65B-7E62-4ED5-A458-FFBF868EE802

P698

Q39640585-6277B325-CE14-4712-88B4-BEB274E18A0A

P921

Q39640585-081A2F62-6E47-4061-A635-714714E7DE80

Q39640585-F43AE14F-F698-4C74-A189-95BE8B3119D9

P356

P1433

Clinical Infectious Diseases

P1476

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

@en

P2093

Dalya Guris

http://www.w3.org/2001/XMLSchema#string

Deborah Molrine

http://www.w3.org/2001/XMLSchema#string

Marilyne Dupin

http://www.w3.org/2001/XMLSchema#string

Mark Leney

http://www.w3.org/2001/XMLSchema#string

Mark Miller

http://www.w3.org/2001/XMLSchema#string

Mary Beth Dorr

http://www.w3.org/2001/XMLSchema#string

Swati B Gupta

http://www.w3.org/2001/XMLSchema#string

T Christopher Mast

http://www.w3.org/2001/XMLSchema#string

Vinay Mehta

http://www.w3.org/2001/XMLSchema#string

Xuemei Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Toxin B is essential for virulence of Clostridium difficile

Fecal microbiota transplantation for the treatment of Clostridium difficile infection

Treatment with monoclonal antibodies against Clostridium difficile toxins.

The role of toxin A and toxin B in Clostridium difficile infection.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Burden of Clostridium difficile infection in the United States.

Predictors of first recurrence of Clostridium difficile infection: implications for initial management

Treatment of recurrent Clostridium difficile-associated disease.

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.

Multicenter study of Clostridium difficile infection rates from 2000 to 2006

P304

730-734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIW364

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Erik R Dubberke

P577

2016-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27365387

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile